Welcome and introductions (ID 1840)
Review of phase III data in advanced HCC (ID 1841)
Navigating HCC treatment decisions: What are the clinical implications for patients? (ID 1842)
Cancer immunotherapy in intermediate or early HCC (ID 1843)
The patient perspective: Awareness and involvement in clinical decision making (ID 1844)
Q&A and meeting close (ID 1845)